Pancreatic Cancer Biomarker Study

Status Active, not recruiting

Clinical Trial Summary

This is a non-treatment, blood collection study to evaluate biomarker panels for the diagnosis and prognosis of pancreatic cancer.

Clinical Trial Description

This is a non-treatment, blood collection study to evaluate biomarker panels for the diagnosis and prognosis of pancreatic cancer. Study participants will be recruited by physician referral or from a list of clinical patients being evaluated for a potential pancreatic abnormality or for potential treatment of pancreatic cancer. Additionally, a surveillance cohort will be recruited among individuals who are being monitored for recurrence following surgical or medical treatment for pancreatic cancer. Peripheral blood specimens will be collected from all participants at time of enrollment. Additional specimens may be collected from surveillance cohort participants no more frequently than once every 3 months as clinically indicated. The specimens will be sent to a clinical lab for sTRA biomarker and CA19-9 analysis. Participants will be followed for 36 months to track clinical outcomes. The performance of the investigation biomarker for the diagnosis, prognosis, or surveillance of pancreatic cancer will be compared to the performance of CA19-9. ;

Study Design

Related Conditions & MeSH terms

Pancreatic Adenocarcinoma

Clinical Trial Details

NCT number	NCT04143152
Study type	Observational
Source	Van Andel Research Institute
Contact
Status	Active, not recruiting
Phase
Start date	January 1, 2021
Completion date	October 31, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05305001` - Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico
Recruiting	`NCT05059444` - ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Completed	`NCT01959672` - Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer	Phase 2
Recruiting	`NCT03673423` - Evaluation of the Interobserver Agreement on the Resectability Status of Patients With a Pancreatic Cancer
Terminated	`NCT02495896` - Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors	Phase 1
Recruiting	`NCT05351983` - Patient-derived Organoids Drug Screen in Pancreatic Cancer	N/A
Not yet recruiting	`NCT06026943` - Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer Emitters for the Treatment of Locally Advanced Pancreatic Cancer	N/A
Completed	`NCT03054987` - Endoscopic Ultrasound and Endoscopic Retrograde Cholangiopancreatography for Malignant Distal Biliary Obstruction	N/A
Terminated	`NCT02345460` - Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study	Phase 2
Recruiting	`NCT02072616` - Detection of Circulating Tumor Cells for the Diagnostic of Pancreatic Adenocarcinoma.	Phase 3
Completed	`NCT02174887` - Biological Effect of Nab-paclitaxel Combined to Gemcitabine in Metastatic Pancreatic Cancer	Phase 1
Recruiting	`NCT03703063` - Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer	Phase 1
Terminated	`NCT04077372` - Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal Cancers	N/A
Recruiting	`NCT03073785` - Hypofractionated Stereotactic Body Radiation & Fluorouracil or Capecitabine for Locally Advanced Pancreatic Cancer	Phase 2
Completed	`NCT03665441` - Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC	Phase 3
Recruiting	`NCT04627246` - Personalized Vaccine With SOC Chemo Followed by Nivo in Pancreatic Cancer	Phase 1
Not yet recruiting	`NCT06217666` - Study Examining the Safety and Toxicity of Stereotactic Body Radiotherapy (SBRT) Followed by PCX12 Immunotherapy Delivered by Intratumoral Injection for the Treatment of Patients With Locally Advanced Pancreatic Adenocarcinoma (LAPC)	Phase 1
Recruiting	`NCT05585320` - A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors	Phase 1/Phase 2
Completed	`NCT04119362` - PARAGON Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer
Completed	`NCT03105921` - Irreversible Electroporation (NanoKnife) for the Treatment of Pancreatic Adenocarcinoma	N/A